Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Cell-based systems to assess nuclear receptor activation and their use in drug development.

Raucy JL, Lasker JM.

Drug Metab Rev. 2013 Feb;45(1):101-9. doi: 10.3109/03602532.2012.737333. Review.

PMID:
23330544
2.

Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships.

Fahmi OA, Raucy JL, Ponce E, Hassanali S, Lasker JM.

Drug Metab Dispos. 2012 Nov;40(11):2204-11. doi: 10.1124/dmd.112.047456. Epub 2012 Aug 21.

PMID:
22912432
3.

Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway.

Hsu MH, Savas U, Lasker JM, Johnson EF.

J Pharmacol Exp Ther. 2011 Apr;337(1):125-36. doi: 10.1124/jpet.110.175851. Epub 2011 Jan 4.

4.

Current in vitro high throughput screening approaches to assess nuclear receptor activation.

Raucy JL, Lasker JM.

Curr Drug Metab. 2010 Nov;11(9):806-14. Review.

PMID:
21189134
5.

Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model.

Savas U, Machemer DE, Hsu MH, Gaynor P, Lasker JM, Tukey RH, Johnson EF.

J Biol Chem. 2009 Jun 12;284(24):16541-52. doi: 10.1074/jbc.M902074200. Epub 2009 Apr 14.

6.

Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies.

Hirani V, Yarovoy A, Kozeska A, Magnusson RP, Lasker JM.

Arch Biochem Biophys. 2008 Oct 1;478(1):59-68. doi: 10.1016/j.abb.2008.06.025. Epub 2008 Jul 16.

7.

Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11.

Dhar M, Sepkovic DW, Hirani V, Magnusson RP, Lasker JM.

J Lipid Res. 2008 Mar;49(3):612-24. Epub 2007 Dec 7.

8.

Dynamic optical imaging of vascular and metabolic reactivity in rheumatoid joints.

Lasker JM, Fong CJ, Ginat DT, Dwyer E, Hielscher AH.

J Biomed Opt. 2007 Sep-Oct;12(5):052001.

9.

Digital lock-in algorithm for biomedical spectroscopy and imaging instruments with multiple modulated sources.

Masciotti JM, Lasker JM, Hielscher AH.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:3198-201.

PMID:
17947014
10.

Digital-signal-processor-based dynamic imaging system for optical tomography.

Lasker JM, Masciotti JM, Schoenecker M, Schmitz CH, Hielscher AH.

Rev Sci Instrum. 2007 Aug;78(8):083706.

PMID:
17764328
11.

Kidney dysfunction and hypertension: role for cadmium, p450 and heme oxygenases?

Satarug S, Nishijo M, Lasker JM, Edwards RJ, Moore MR.

Tohoku J Exp Med. 2006 Mar;208(3):179-202. Review.

12.

Renal and hepatic accumulation of cadmium and lead in the expression of CYP4F2 and CYP2E1.

Baker JR, Edwards RJ, Lasker JM, Moore MR, Satarug S.

Toxicol Lett. 2005 Nov 15;159(2):182-91.

PMID:
15994032
13.

Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.

Hirani VN, Raucy JL, Lasker JM.

Drug Metab Dispos. 2004 Dec;32(12):1462-7. Epub 2004 Sep 24.

PMID:
15448116
14.

Aerobic oxidation of methyl p-tolyl sulfide catalyzed by a remarkably labile heteroscorpionate RuII-aqua complex, fac-[RuII(H2O)(dpp)(tppm)]2+.

Huynh MH, Witham LM, Lasker JM, Wetzler M, Mort B, Jameson DL, White PS, Takeuchi KJ.

J Am Chem Soc. 2003 Jan 15;125(2):308-9.

PMID:
12517123
16.

Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes.

Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM.

J Pharmacol Exp Ther. 2002 Aug;302(2):475-82.

PMID:
12130704
17.

Remarkable spectator ligand effect on the rate constant of ligand substitution of (aqua)ruthenium(II) complexes.

Huynh MH, Lasker JM, Wetzler M, Mort B, Szczepura LF, Witham LM, Cintron JM, Marschilok AC, Ackerman LJ, Castellano RK, Jameson DL, Churchill MR, Jircitano AJ, Takeuchi KJ.

J Am Chem Soc. 2001 Sep 12;123(36):8780-4.

PMID:
11535083
18.
19.

CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.

Wester MR, Lasker JM, Johnson EF, Raucy JL.

Drug Metab Dispos. 2000 Mar;28(3):354-9.

PMID:
10681382
20.

Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11.

Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK.

J Biol Chem. 2000 Feb 11;275(6):4118-26.

21.

Role of human CYP4F2 in hepatic catabolism of the proinflammatory agent leukotriene B4.

Jin R, Koop DR, Raucy JL, Lasker JM.

Arch Biochem Biophys. 1998 Nov 1;359(1):89-98.

PMID:
9799565
22.
23.

Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.

Lasker JM, Wester MR, Aramsombatdee E, Raucy JL.

Arch Biochem Biophys. 1998 May 1;353(1):16-28.

PMID:
9578596
24.

Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3'-azido-3'-deoxythymidine (AZT) to 3'-amino-3'-deoxythymidine.

Pan-Zhou XR, Cretton-Scott E, Zhou XJ, Yang MX, Lasker JM, Sommadossi JP.

Biochem Pharmacol. 1998 Mar 15;55(6):757-66.

PMID:
9586947
25.

Identification of CYP4A11 as the major lauric acid omega-hydroxylase in human liver microsomes.

Powell PK, Wolf I, Lasker JM.

Arch Biochem Biophys. 1996 Nov 1;335(1):219-26.

PMID:
8914854
26.

Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.

Karam WG, Goldstein JA, Lasker JM, Ghanayem BI.

Drug Metab Dispos. 1996 Oct;24(10):1081-7.

PMID:
8894508
27.

Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.

Feierman DE, Lasker JM.

Drug Metab Dispos. 1996 Sep;24(9):932-9.

PMID:
8886601
28.

1-Hydroxyethyl radical formation during NADPH- and NADH-dependent oxidation of ethanol by human liver microsomes.

Rao DN, Yang MX, Lasker JM, Cederbaum AI.

Mol Pharmacol. 1996 May;49(5):814-21.

PMID:
8622631
29.
30.

Serum carbohydrate-deficient transferrin: mechanism of increase after chronic alcohol intake.

Xin Y, Lasker JM, Lieber CS.

Hepatology. 1995 Nov;22(5):1462-8.

PMID:
7590664
31.

Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9.

Daikh BE, Lasker JM, Raucy JL, Koop DR.

J Pharmacol Exp Ther. 1994 Dec;271(3):1427-33.

PMID:
7996455
32.

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.

Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI.

Biochemistry. 1994 Feb 22;33(7):1743-52.

PMID:
8110777
33.

In vivo induction of hepatic P4502E1 by ethanol: role of increased enzyme synthesis.

Tsutsumi M, Lasker JM, Takahashi T, Lieber CS.

Arch Biochem Biophys. 1993 Jul;304(1):209-18.

PMID:
8323286
34.

Induction of P4502E1 by acetone in isolated rabbit hepatocytes. Role of increased protein and mRNA synthesis.

Kraner JC, Lasker JM, Corcoran GB, Ray SD, Raucy JL.

Biochem Pharmacol. 1993 Apr 6;45(7):1483-92.

PMID:
8471070
35.
36.

Bioactivation of halogenated hydrocarbons by cytochrome P4502E1.

Raucy JL, Kraner JC, Lasker JM.

Crit Rev Toxicol. 1993;23(1):1-20. Review.

PMID:
8471158
37.
39.

Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol.

Bornheim LM, Lasker JM, Raucy JL.

Drug Metab Dispos. 1992 Mar-Apr;20(2):241-6.

PMID:
1352216
40.
41.

Effects of ethanol consumption on bioactivation and hepatotoxicity of N-nitrosodimethylamine in rats.

Ma XL, Baraona E, Lasker JM, Lieber CS.

Biochem Pharmacol. 1991 Jul 15;42(3):585-91.

PMID:
1859464
42.

Induction of cytochrome P450IIE1 in the obese overfed rat.

Raucy JL, Lasker JM, Kraner JC, Salazar DE, Lieber CS, Corcoran GB.

Mol Pharmacol. 1991 Mar;39(3):275-80.

PMID:
2005876
43.

Isolation of P450 enzymes from human liver.

Raucy JL, Lasker JM.

Methods Enzymol. 1991;206:577-87. No abstract available.

PMID:
1664480
44.

Immunohistochemical localization of ethanol-inducible P450IIE1 in the rat alimentary tract.

Shimizu M, Lasker JM, Tsutsumi M, Lieber CS.

Gastroenterology. 1990 Oct;99(4):1044-53.

PMID:
2203661
45.

The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver.

Tsutsumi M, Lasker JM, Shimizu M, Rosman AS, Lieber CS.

Hepatology. 1989 Oct;10(4):437-46.

PMID:
2673969
46.

Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2.

Raucy JL, Lasker JM, Lieber CS, Black M.

Arch Biochem Biophys. 1989 Jun;271(2):270-83.

PMID:
2729995
47.

Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8.

Leo MA, Lasker JM, Raucy JL, Kim CI, Black M, Lieber CS.

Arch Biochem Biophys. 1989 Feb 15;269(1):305-12.

PMID:
2916844
48.

Role of acetone, dietary fat and total energy intake in induction of hepatic microsomal ethanol oxidizing system.

Lieber CS, Lasker JM, DeCarli LM, Saeli J, Wojtowicz T.

J Pharmacol Exp Ther. 1988 Nov;247(2):791-5.

PMID:
3183973
49.

Formation of acetaldehyde adducts with ethanol-inducible P450IIE1 in vivo.

Behrens UJ, Hoerner M, Lasker JM, Lieber CS.

Biochem Biophys Res Commun. 1988 Jul 29;154(2):584-90.

PMID:
3401224
50.

Molecular regulation of ethanol-inducible cytochrome P450-IIEI in hamsters.

Kubota S, Lasker JM, Lieber CS.

Biochem Biophys Res Commun. 1988 Jan 15;150(1):304-10.

PMID:
2447892

Supplemental Content

Loading ...
Support Center